Imatinib Treatment Induces CD5+ B Lymphocytes and IgM Natural Antibodies with Anti-Leukemic Reactivity in Patients with Chronic Myelogenous Leukemia

Immunoprofiling of patients with chronic myeloid leukemia at diagnosis and during tyrosine kinase inhibitor therapy

(2010) Peter Rohon et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

Bone marrow mesenchymal stromal cells non-selectively protect chronic myeloid leukemia cells from imatinib-induced apoptosis via the CXCR4/CXCL12 axis

(2010) F. Vianello et al.   HAEMATOLOGICA

Abnormal phenotype of bone marrow plasma cells in patients with chronic myeloid leukemia undergoing therapy with Imatinib

(2010) Giovanni Carulli et al.   LEUKEMIA RESEARCH

Efficacy of imatinib dose escalation in patients with chronic myeloid leukemia in chronic phase

(2009) Hagop M. Kantarjian et al.   CANCER

Effects of imatinib mesylate in osteoblastogenesis

(2009) Daniele Tibullo et al.   EXPERIMENTAL HEMATOLOGY

Choosing the best treatment strategy for chronic myeloid leukemia patients resistant to imatinib: weighing the efficacy and safety of individual drugs with BCR-ABL mutations and patient history

(2009) E Jabbour et al.   LEUKEMIA

Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia

(2009) A Hochhaus et al.   LEUKEMIA

Cytotoxic natural antibodies against human tumours: An option for anti-cancer immunotherapy?

(2008) Reinhard Schwartz-Albiez et al.   AUTOIMMUNITY REVIEWS

A Novel Bone Morphogenetic Protein Signaling in Heterotypic Cell Interactions in Prostate Cancer

(2008) S. Yang et al.   CANCER RESEARCH